Teruyuki Hirano

Prof. Teruyuki Hirano

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2009 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
MNMakoto Nakajima
Makoto Nakajima
THTeruyuki Hirano
Teruyuki Hirano
HNHiroaki Naritomi
Hiroaki Naritomi
KMKazuo Minematsu
Kazuo Minematsu
Background: The aim of this study was to investigate whether progression or fluctuation of transient ischemic attack (TIA) symptoms is a predictor of subsequent stroke. Methods: We prospectively analyzed 113 consecutive patients admitted with a diagnosis of classical TIA with symptom duration of less than 24 h. We assessed the background characteristics, TIA symptoms, attack characteristics, results of in-hospital examinations, and prescription of antithrombotic agents on discharge for each patient. We then analyzed the factors related to progression or fluctuation of TIA symptoms. Results: Of the 113 patients, 35 (31.0%) exhibited symptom progression or fluctuation. Subsequent stroke occurred in 12 (10.6%) patients within 180 days. Symptom progression or fluctuation was significantly related to the TIA symptoms of speech disturbance, hemiparesis, and monoparesis, and were also related to subsequent stroke occurrence within 90 days (29 vs. 3%, p = 0.004) and 180 days (23 vs. 5%, p = 0.008). In a logistic regression model analysis, symptom progression or fluctuation was a significant predictor of subsequent stroke within 90 days (odds ratio = 7.65, 95% CI 1.27–46.06) and 180 days (odds ratio = 4.44, 95% CI 1.08–18.13), independently of other predictors demonstrated in previous studies. Conclusions: Progression or fluctuation of TIA symptoms may be an important predictor of subsequent stroke. A detailed interview about the characteristics of each attack is also indispensable for the provision of appropriate care to TIA patients.

1 September 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SAShahram Abootalebi
Shahram Abootalebi
BABenjamin M. Aertker
Benjamin M. Aertker
MAMohammadsobhan Sheikh Andalibi
Mohammadsobhan Sheikh Andalibi
NANegar Asdaghi
Negar Asdaghi
ÖAözlem Aykaç
özlem Aykaç
Ramin ZandRamin Zand
Ramin Zand

1 February 2024 in Stroke
Verified
Journal Article
Closed access
ESEric E Smith
Eric E Smith
ASAshkan Shoamanesh
Ashkan Shoamanesh
LXLizhen Xu
Lizhen Xu
LHLaura Heenan
Laura Heenan
FSFeryal Saad
Feryal Saad
PIPACIFIC-Stroke Steering Committee and Investigators
PACIFIC-Stroke Steering Committee and Investigators
BACKGROUND: Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334—Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in patients enrolled with large, multiple, or cortical acute infarcts on magnetic resonance imaging than in patients enrolled with a single small subcortical acute infarct, and asundexian would prevent incident cortical covert infarcts. METHODS: In this placebo-controlled double-blinded randomized controlled trial, patients with mild-to-moderate noncardioembolic ischemic stroke were assigned to asundexian (10, 20, or 50 mg once daily) or placebo, in addition to antiplatelet therapy. Brain magnetic resonance imagings were required within 72 hours of randomization and repeated at 26 weeks or at discontinuation of the study drug. RESULTS: Of 1808 randomized patients, 1780 (98.5%) had interpretable baseline magnetic resonance imagings, of which 1628 (91.5%) had ≥1 diffusion-weighted imaging positive acute infarcts. Magnetic resonance imaging follow-up was obtained in 1439 patients, of whom 1358 had no symptomatic stroke during the trial period. Compared with placebo, asundexian 50 mg daily conferred a trend toward reduced risk of recurrent ischemic stroke or incident covert infarcts (hazard ratio, 0.71 [95% CI, 0.45–1.11]) and recurrent ischemic stroke or transient ischemic attack (secondary outcome; hazard ratio, 0.59 [95% CI, 0.33–1.06]) that was not evident in patients with single small subcortical infarcts (hazard ratios, 1.14 [95% CI, 0.62–2.10] and 0.93 [95% CI, 0.28–3.06]). Incident cortical covert infarcts were reduced in patients taking asundexian 50 mg, but the difference was not statistically significant (crude incidence ratio, 0.56 [95% CI, 0.28–1.12]). CONCLUSIONS: These exploratory, unconfirmed results suggest that asundexian may prevent new embolic infarcts but not small artery occlusion. The hypothesis that subtypes of covert brain infarcts respond differently to anticoagulant prevention should be tested in future trials. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT04304508.

3 May 2013
Verified
Book Chapter
Closed access
PDF file
THTeruyuki Hirano
Teruyuki Hirano
Thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) is established as an effective treatment for patients with acute ischemic stroke. No distinction to the presence of chronic kidney disease (CKD) was made in previous clinical trials. In this chapter, three clinical studies that investigated renal dysfunction on the effect of rt-PA were reviewed and a meta-analysis was performed. In total, 344 patients with CKD and 504 patients without were treated within 3 h of symptom onset. Patients with CKD showed decreased odds of being alive and independent compared to patients with normal renal function (OR 0.60, 95% CI 0.45-0.81). Symptomatic intracranial hemorrhage occurred more in patients with CKD than without (OR 3.38, 95% CI 1.60-7.15). Risk of fatal outcome was also significantly higher in patients with CKD (OR 3.15, 95% CI 1.82-5.45).

1 October 2017 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
THTeruyuki Hirano
Teruyuki Hirano
HKHirokazu Kaneko
Hirokazu Kaneko
SMSari Mishina
Sari Mishina
FWFeng Wang
Feng Wang
SMSatoshi Morita
Satoshi Morita
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia, with increasing prevalence in Japan. Although prothrombin time-international normalized ratio (PT-INR) targets for monitoring warfarin therapy in patients with nonvalvular AF (NVAF) are well defined, real-world patient characteristics and PT-INR levels remain unknown among Japanese patients with NVAF who initiate and continue warfarin (warfarin maintainers) versus those who switch from warfarin to direct oral anticoagulants (DOACs; warfarin switchers). Methods: Patients with NVAF receiving oral anticoagulants between February 2013 and June 2015 were identified using a nationwide electronic medical record (EMR) database from 69 hospitals in Japan. Demographics and characteristics of patients, PT-INR, time in therapeutic range (TTR), and frequency in range (FIR) of PT-INR between warfarin maintainers and warfarin switchers were assessed. Results: A total of 1705 patients met inclusion criteria and were examined (1501 warfarin maintainers versus 204 warfarin switchers). CHADS(2), CHA(2)DS(2)-VASc, and HAS-BLED scores were comparable between groups. However, these scores were significantly higher among warfarin switchers at the time of switching than at the time of warfarin initiation. Furthermore, TTR and FIR of PT-INR were lower in warfarin switchers than in maintainers. Nevertheless, TTR and FIR were below 50% (PT-INR, 1.6-2.6) in both patient groups. Conclusions: In this EMR-based clinical study, patients who switched to DOACs had both poor or inadequate PT-INR control and higher risk factors of stroke. Many patients receiving warfarin did not achieve sufficient PT-INR therapeutic range. DOACs could be recommended in Japanese patients with NVAF with inadequate PT-INR control and increased risk of stroke.

5 February 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KTKeisuke Tokunaga
Keisuke Tokunaga
MKMasatoshi Koga
Masatoshi Koga
RIRyo Itabashi
Ryo Itabashi
HYHiroshi Yamagami
Hiroshi Yamagami
KTKenichi Todo
Kenichi Todo
KMKazuo Minematsu
Kazuo Minematsu
Background: We aimed to clarify associations between prior anticoagulation and short‐ or long‐term clinical outcomes in ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation. Methods and Results: A total of 1189 ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation who were hospitalized within 7 days after onset were analyzed. Of these, 813 patients (68.4%) received no prior anticoagulation, 310 (26.1%) received prior warfarin treatment with an international normalized ratio ( INR ) <2 on admission, 28 (2.4%) received prior warfarin treatment with an INR ≥2 on admission, and the remaining 38 (3.2%) received prior direct oral anticoagulant treatment. Prior warfarin treatment was associated with a lower risk of death or disability at 3 months compared with no prior anticoagulation ( INR <2: adjusted odds ratio: 0.58; 95% CI, 0.42–0.81; P =0.001; INR ≥2: adjusted odds ratio: 0.40; 95% CI, 0.16–0.97; P =0.043) but was not associated with a lower risk of death or disability at 2 years. Prior warfarin treatment with an INR ≥2 on admission was associated with a higher risk of ischemic events within 2 years compared with no prior anticoagulation (adjusted hazard ratio: 2.94; 95% CI, 1.20–6.15; P =0.021). Conclusions: Prior warfarin treatment was associated with a lower risk of death or disability at 3 months but was not associated with a lower risk of death or disability at 2 years in ischemic stroke or transient ischemic attack patients with nonvalvular atrial fibrillation. Prior warfarin treatment with an INR ≥2 on admission was associated with a higher risk of ischemic events within 2 years. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01581502.